Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LVIVO-TaVec122 in Relapsed/Refractory B-cell Malignancies
NCT07628582Phase 1Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Sep 2026
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LVIVO-TaVec122 in non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL), sponsored by Jiangsu Provincial People's Hospital. Primary endpoints: Incidence, severity, and type of treatment-emergent adverse events at 2 years, Pharmacokinetics in peripheral blood at 2 years and 2 more. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
LVIVO-TaVec122
03
Conditions
non-Hodgkin lymphoma (NHL)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT07628582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07628582.